GSK2881078

ID: gsk2881078

Aliases: GSK-2881078

Type: compound

Route/form: oral investigational drug

Status: investigational

Evidence level: early human

Best data tier: early human + human controlled/review

Support scope: human

Source types: early_human, human_rct, systematic_review

Linked sources: 3

Broad outcomes: Fat loss / metabolic health, Muscle growth / performance / recovery, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• androgen receptor modulator
• nonsteroidal SARM

Optimization domains

• SARM
• muscle wasting
• body composition
• early clinical

Research basis

• GSK2881078 adds a clinically tested SARM program outside bodybuilding: phase 1 healthy-volunteer data and a phase 2A COPD muscle-weakness trial.
• The COPD trial is useful because it pairs SARM exposure with exercise and measures lean mass/strength/function rather than only receptor binding.
• It shows the best-case SARM development logic: oral AR modulation aimed at muscle weakness with disease-context monitoring.

Limits, risks, and missing evidence

• COPD muscle weakness and healthy-volunteer pharmacology do not establish healthy-user cycle efficacy or long-term safety.
• Sex-specific endpoint interpretation and functional-outcome uncertainty matter even in the clinical program.
• Class endocrine, lipid, liver, androgen-sensitive tissue, and doping concerns still need compound-specific long-term data.

Risk flags

• investigational
• sarm class risk
• endpoint translation uncertain
• doping

Linked papers, labels, and reviews

1. Safety, pharmacokinetics and pharmacological effects of GSK2881078
   early_human / pubmed_gsk2881078_phase1_2017
   Phase 1 study in healthy men and postmenopausal women.
2. Selective Androgen Receptor Modulators effects on physical performance: a systematic review of randomized control trials
   systematic_review / pubmed_sarms_rct_systematic_review_2024
   Systematic review of randomized SARM trials and physical-performance endpoints.
3. Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial
   human_rct / pubmed_gsk2881078_copd_phase2_2022
   Phase 2A COPD muscle-weakness trial of oral GSK2881078 plus exercise; disease-context SARM signal with sex-specific endpoint interpretation.